Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group

vanMeerbeeck, J
Debruyne, C
vanZandwijk, N
Postmus, PE
Pennucci, MC
vanBreukelen, F
Galdermans, D
Groen, H
Pinson, P
vanGlabbeke, M
vanMarck, E
Giaccone, G

Publication date

September 1996

Abstract

The EORTC Lung Cancer Cooperative Group undertook a phase II study of paclitaxel in 25 chemotherapy-naive patients with malignant pleural mesothelioma. Paclitaxel was given intravenously at a dose of 200 mg m(-2), as a 3 h infusion every 3 weeks, after standard premedication with corticosteroids and antihistamines. This regimen was well tolerated, with <4% of cycles resulting in severe toxicity. No major objective responses were observed and ten patients had stable disease. Median survival time was 39 weeks and the 1 year survival rate was 30%. In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma

Extracted data

We use cookies to provide a better user experience.

Data Protection

Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group

Abstract

Extracted data

Paclitaxel for malignant pleural mesothelioma: A phase II study of the EORTC Lung Cancer Cooperative Group

Abstract

Extracted data

Related items

Related items